A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and oxaliplatin in patients with advanced solid tumors

Απλή σελίδα τεκμηρίου
dc.contributor.authorKalbakis, K.en
dc.contributor.authorPappas, P.en
dc.contributor.authorKouroussis, C.en
dc.contributor.authorVamvakas, L.en
dc.contributor.authorKalykaki, A.en
dc.contributor.authorVardakis, N.en
dc.contributor.authorNikolaidou, M.en
dc.contributor.authorMarselos, M.en
dc.contributor.authorGeorgoulias, V.en
dc.contributor.authorMavroudis, D.en
dc.date.accessioned2015-11-24T19:40:27Z
dc.date.available2015-11-24T19:40:27Z
dc.identifier.issn0344-5704-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/24356
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subject*Antineoplastic Combined Chemotherapy Protocols/administration & dosage/adverseen
dc.subjecteffects/pharmacokinetics/therapeutic useen
dc.subjectDisease-Free Survivalen
dc.subjectDose-Response Relationship, Drugen
dc.subjectDoxorubicin/administration & dosage/adverse effects/pharmacokinetics/therapeuticen
dc.subjectuseen
dc.subjectDrug Administration Scheduleen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectNeoplasm Invasivenessen
dc.subjectNeoplasms/*drug therapy/pathologyen
dc.subjectOrganoplatinum Compounds/administration & dosage/adverseen
dc.subjecteffects/pharmacokinetics/therapeutic useen
dc.subjectPaclitaxel/administration & dosage/adverse effects/pharmacokinetics/therapeuticen
dc.subjectuseen
dc.titleA dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and oxaliplatin in patients with advanced solid tumorsen
heal.abstractPURPOSE: To evaluate the maximum tolerated doses (MTD) and the dose-limiting toxicities (DLT) of the combination of pegylated liposomal doxorubicin (PEG-LD), paclitaxel and oxaliplatin (L-OHP) administered every 2 weeks in patients with advanced solid tumors. METHODS: Thirty-nine pretreated patients with advanced solid tumors received escalated doses of PEG-LD (10-16 mg/m(2)), paclitaxel (100-120 mg/m(2)) and L-OHP (50-70 mg/m(2)) every 2 weeks. As one cycle of treatment was considered the administration of both drugs on days 1 and 15 of a 4-week cycle. RESULTS: The MTDs were PEG-LD 14 mg/m(2), paclitaxel 120 mg/m(2) and L-OHP 70 mg/m(2). Neutropenia was the DLT in all but one case with only one episode of febrile neutropenia and no toxic deaths. Four (4%) and 13 (12%) cycles were complicated by grades 4 and 3 neutropenia, respectively. Grades 2-3 fatigue and neurotoxicity occurred in 13 and 12% of cycles, respectively. Responses were observed in patients with breast, endometrial and ovarian carcinomas. CONCLUSIONS: This is a quite well-tolerated regimen which merits further evaluation in phase II studies.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.primary10.1007/s00280-007-0624-3-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/17960381-
heal.identifier.secondaryhttp://www.springerlink.com/content/7447319178378k8w/fulltext.pdf-
heal.journalNameCancer Chemother Pharmacolen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate2008-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ